Allergan plc. (NYSE:AGN)

Home >> Stock >> Allergan plc. >> Reports

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, central nervous system, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; In addition, it develops medical and cosmetic treatments; treatments for neurodegenerative disorders; and inflammatory and fibrotic diseases. It has a collaboration, option, and license agreement with Lyndra, Inc. to develop orally administered products for the treatment of Alzheimer's disease; strategic alliance and option agreement with Editas Medicine, Inc.; and Allergan plc also has licensing agreements with Assembly Biosciences, Inc. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was incorporated in 2013 and is headquartered in Dublin, Ireland....

+See More
See More

Blog+More

AYA finbuzz podcast offers fresh insights into the latest stock market issues and economic trends for better and wiser investment decisions.

Amy Hamilton

2019-06-30 12:37:00 Sunday ET

AYA finbuzz podcast offers fresh insights into the latest stock market issues and economic trends for better and wiser investment decisions.

AYA Analytica finbuzz podcast channel on YouTube June 2019 In this podcast, we discuss several topical issues as of June 2019: (1) Federal Reserve h

+See More

Thomas Piketty connects the dots between economic growth and inequality worldwide with long-term global empirical evidence.

Chanel Holden

2023-05-28 10:24:00 Sunday ET

Thomas Piketty connects the dots between economic growth and inequality worldwide with long-term global empirical evidence.

Thomas Piketty connects the dots between economic growth and inequality worldwide with long-term global empirical evidence. Thomas Piketty (2017) &nbs

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More

Thomas Sowell argues that some economic reforms inadvertently exacerbate economic disparities.

Daisy Harvey

2023-11-14 08:24:00 Tuesday ET

Thomas Sowell argues that some economic reforms inadvertently exacerbate economic disparities.

Thomas Sowell argues that some economic reforms inadvertently exacerbate economic disparities. Thomas Sowell (2019)   Discrimination and econo

+See More

White House chief economic adviser Larry Kudlow points out that the recent U.S. dollar strength shows a clear sign of investor optimism.

James Campbell

2018-08-13 12:39:00 Monday ET

White House chief economic adviser Larry Kudlow points out that the recent U.S. dollar strength shows a clear sign of investor optimism.

White House chief economic adviser Larry Kudlow points out that the recent U.S. dollar strength shows a clear sign of investor confidence and optimism. Gree

+See More

U.S. Treasury's proposal for financial deregulation aims to remove key aspects of the Dodd-Frank Act.

Rose Prince

2017-08-25 13:36:00 Friday ET

U.S. Treasury's proposal for financial deregulation aims to remove key aspects of the Dodd-Frank Act.

The U.S. Treasury's June 2017 grand proposal for financial deregulation aims to remove several aspects of the Dodd-Frank Act 2010 such as annual macro s

+See More